HUP0400032A3 - Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg - Google Patents

Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Info

Publication number
HUP0400032A3
HUP0400032A3 HU0400032A HUP0400032A HUP0400032A3 HU P0400032 A3 HUP0400032 A3 HU P0400032A3 HU 0400032 A HU0400032 A HU 0400032A HU P0400032 A HUP0400032 A HU P0400032A HU P0400032 A3 HUP0400032 A3 HU P0400032A3
Authority
HU
Hungary
Prior art keywords
ocd
gvg
obsessive
related disorders
compulsive disorder
Prior art date
Application number
HU0400032A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of HUP0400032A2 publication Critical patent/HUP0400032A2/hu
Publication of HUP0400032A3 publication Critical patent/HUP0400032A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400032A 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg HUP0400032A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
PCT/US2002/014344 WO2002092071A1 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Publications (2)

Publication Number Publication Date
HUP0400032A2 HUP0400032A2 (hu) 2004-04-28
HUP0400032A3 true HUP0400032A3 (en) 2012-09-28

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400032A HUP0400032A3 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg

Country Status (18)

Country Link
US (2) US6462084B1 (enExample)
EP (1) EP1392273A4 (enExample)
JP (1) JP2004533445A (enExample)
KR (1) KR20040028758A (enExample)
CN (1) CN1509168A (enExample)
BR (1) BR0209614A (enExample)
CA (1) CA2446641A1 (enExample)
CZ (1) CZ20033379A3 (enExample)
HR (1) HRP20030894A2 (enExample)
HU (1) HUP0400032A3 (enExample)
IL (1) IL158761A0 (enExample)
MX (1) MXPA03010406A (enExample)
NO (1) NO20035037L (enExample)
NZ (1) NZ529613A (enExample)
PL (1) PL367362A1 (enExample)
TW (1) TWI313599B (enExample)
WO (1) WO2002092071A1 (enExample)
YU (1) YU89103A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
WO2004096269A2 (en) * 2003-04-25 2004-11-11 Allergan, Inc. Botulinum neurotoxin for treating tics and obsessive compulsive behaviors
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0767174A1 (de) 1991-11-21 1997-04-09 Ciba-Geigy Ag Neue Aminoalkanphosphinsäuren und ihre Salze
DK0641330T3 (da) * 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
EP0915697B1 (en) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
MXPA01004015A (es) * 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
MXPA01007758A (es) 1999-02-01 2003-06-24 Johnson & Johnson Uso de derivados de anticonvulsivos para tratar la bulimia nerviosa.
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Also Published As

Publication number Publication date
CA2446641A1 (en) 2002-11-21
JP2004533445A (ja) 2004-11-04
NO20035037L (no) 2004-01-07
PL367362A1 (en) 2005-02-21
HRP20030894A2 (en) 2004-06-30
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (en) 2002-11-21
BR0209614A (pt) 2004-12-07
YU89103A (sh) 2006-08-17
KR20040028758A (ko) 2004-04-03
NZ529613A (en) 2006-09-29
CZ20033379A3 (cs) 2004-12-15
EP1392273A4 (en) 2004-11-24
US20020169103A1 (en) 2002-11-14
HUP0400032A2 (hu) 2004-04-28
CN1509168A (zh) 2004-06-30
IL158761A0 (en) 2004-05-12
EP1392273A1 (en) 2004-03-03
NO20035037D0 (no) 2003-11-13
US6462084B1 (en) 2002-10-08
TWI313599B (en) 2009-08-21

Similar Documents

Publication Publication Date Title
AU2002358934A1 (en) Pelvic disorder treatment device
AU2002365075A8 (en) Apparatus and methods for treating spinal discs
ZA200309762B (en) Rock-bolting apparatus and method.
GB0115980D0 (en) Apparatus and methods
GB0512558D0 (en) Microorganisms for well treatment
GB0113751D0 (en) Surface treatment
GB0129976D0 (en) Treatment method
HUP0400032A2 (hu) Rögeszmés-kényszeres zavarok (OCD) és OCD-rokon rendellenességek új kezelése GVG alkalmazásával
GB0120147D0 (en) Treatment method
HUP0303303A3 (en) Treatment bed, treatment apparatus and treatment device
GB0101244D0 (en) Process and apparatus
GB0105899D0 (en) Fibrosis reduction treatment
GB0130763D0 (en) Treatment methods
AU2002101010A4 (en) Treatment process and apparatus
GB0103031D0 (en) Novel treatment
GB2376239B (en) Cask treatment
GB0126253D0 (en) Treatment method
GB2378387B (en) Apparatus for beauty treatment
GB0110108D0 (en) Drinking apparatus
AU2002229796A1 (en) Method for treating sleep disorders
GB0130694D0 (en) Treatment
GB2413797B (en) Microorganisms for well treatment
GB0102927D0 (en) Treatment method
IL162193A (en) Device for treating pelvic disorders
GB0116837D0 (en) Treatment

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees